Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 23:00 ET | Source: Everest Medicines

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

SHANGHAI, China, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
June 22, 2020 19:00 ET | Source: Everest Medicines

云顶新耀宣布Xerava™（依拉环素）针对人类支原体的体外研究取得重大进展

与其他四种抗生素相比，依拉环素对特定的支原体亚群拥有更强的抗菌效果数据表明，对药物敏感和耐药的支原体引起的一些呼吸道感染，依拉环素可能提供了替代治疗方案中国上海, June 23, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest...
June 22, 2020 19:00 ET | Source: Everest Medicines

Everest Medicines Announces Positive Results of In Vitro Study of Xerava™ (eravacycline) Against Human Mycoplasmas

Xerava demonstrated greater potency against a select group of mycoplasma species in comparison to four other antimicrobials Data suggest Xerava may provide alternative treatment option for some...
June 04, 2020 20:15 ET | Source: Everest Medicines

云顶新耀完成3.1亿美元C轮融资

中国上海, June 05, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港特别行政区、澳门特别行政区以及台湾地区）及其它亚洲市场未满足的医疗需求，今天宣布完成3.1亿美元C轮融资。 ...
June 04, 2020 20:15 ET | Source: Everest Medicines

Everest Medicines Completes US$310 Million Series C Financing

SHANGHAI, China, June 04, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
April 24, 2020 21:15 ET | Source: Everest Medicines

云顶新耀宣布其授权合作伙伴Immunomedics新药Trodelvy (sacituzumab govitecan-hziy)获得美国食品药物管理局加速上市批准，用于既往治疗无效的转移性三阴性乳腺癌患者

中国上海, April 24, 2020 (GLOBE NEWSWIRE) -- 家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港特别行政区、澳门特别行政区以及台湾地区）及其它亚洲市场未满足的医疗需求，今天宣布美国食品药物管理局（FDA）已批准Immunomedics Inc. （纳斯达克股票代码：IMMU）提交的sacituzumab...
April 24, 2020 21:15 ET | Source: Everest Medicines

CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer

SHANGHAI, China, April 24, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, April 24th by Everest Medicines (Nasdaq: IMMU), at the end of the subheading, please note...
April 24, 2020 07:00 ET | Source: Everest Medicines

云顶新耀宣布其授权合作伙伴Immunomedics新药Trodelvy (sacituzumab govitecan-hziy)获得美国食品药物管理局加速上市批准，用于既往治疗无效的转移性三阴性乳腺癌患者

中国上海, April 24, 2020 (GLOBE NEWSWIRE) -- 家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港特别行政区、澳门特别行政区以及台湾地区）及其它亚洲市场未满足的医疗需求，今天宣布美国食品药物管理局（FDA）已批准Immunomedics Inc. （纳斯达克股票代码：IMMU）提交的sacituzumab...
April 24, 2020 07:00 ET | Source: Everest Medicines

Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer

SHANGHAI, China, April 24, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
April 22, 2020 08:00 ET | Source: Everest Medicines

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer

Approval allows Everest Medicines to enroll patients in registration clinical study in ChinaThe US FDA granted Fast Track Designation and Breakthrough Therapy Designation to sacituzumab govitecan for...